Creative Planning’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$80.8M Buy
528,814
+89,851
+20% +$13.8M 0.05% 149
2025
Q4
$60.5M Buy
438,963
+15,145
+4% +$1.98M 0.04% 173
2025
Q3
$54.4M Buy
423,818
+25,560
+6% +$3.12M 0.04% 174
2025
Q2
$48.2M Buy
398,258
+11,267
+3% +$1.27M 0.04% 175
2025
Q1
$43.1M Buy
386,991
+33,232
+9% +$3.54M 0.04% 189
2024
Q4
$34.4M Buy
353,759
+8,808
+3% +$939K 0.03% 198
2024
Q3
$39.7M Buy
344,951
+13,486
+4% +$1.53M 0.04% 172
2024
Q2
$35.3M Buy
331,465
+14,858
+5% +$1.49M 0.04% 180
2024
Q1
$30.6M Buy
316,607
+6,419
+2% +$658K 0.03% 192
2023
Q4
$31.3M Sell
310,188
-137,394
-31% -$13.3M 0.06% 179
2023
Q3
$45.6M Buy
447,582
+146,327
+49% +$14.9M 0.06% 134
2023
Q2
$30.4M Buy
301,255
+14,742
+5% +$1.47M 0.04% 171
2023
Q1
$26.4M Sell
286,513
-2,623
-0.9% -$229K 0.04% 183
2022
Q4
$26.2M Sell
289,136
-12,014
-4% -$1.01M 0.04% 176
2022
Q3
$22.9M Sell
301,150
-11,654
-4% -$966K 0.04% 168
2022
Q2
$26.4M Sell
312,804
-29,662
-9% -$2.6M 0.04% 166
2022
Q1
$30.1M Buy
342,466
+256,185
+297% +$22.2M 0.05% 152
2021
Q4
$7.55M Sell
86,281
-18,846
-18% -$1.56M 0.01% 337
2021
Q3
$8.6M Buy
105,127
+33,024
+46% +$2.97M 0.02% 291
2021
Q2
$6.58M Sell
72,103
-14,140
-16% -$1.26M 0.01% 340
2021
Q1
$7.37M Sell
86,243
-3,170
-4% -$284K 0.01% 328
2020
Q4
$8.44M Buy
89,413
+2,615
+3% +$229K 0.02% 285
2020
Q3
$7.52M Buy
86,798
+11,828
+16% +$1.02M 0.02% 258
2020
Q2
$6.55M Sell
74,970
-14,827
-17% -$1.28M 0.02% 248
2020
Q1
$7.4M Buy
89,797
+12,404
+16% +$1.11M 0.03% 204
2019
Q4
$7.33M Buy
77,393
+3,400
+5% +$305K 0.02% 241
2019
Q3
$6.43M Buy
73,993
+328
+0.4% +$29.4K 0.02% 244
2019
Q2
$6.73M Sell
73,665
-4,391
-6% -$372K 0.02% 237
2019
Q1
$6.72M Sell
78,056
-3,158
-4% -$254K 0.02% 219
2018
Q4
$6.25M Buy
81,214
+2,485
+3% +$193K 0.03% 207
2018
Q3
$6.08M Buy
78,729
+14,148
+22% +$1.05M 0.02% 237
2018
Q2
$4.37M Buy
64,581
+450
+0.7% +$31.1K 0.02% 281
2018
Q1
$4.65M Sell
64,131
-2,580
-4% -$196K 0.02% 259
2017
Q4
$5.02M Buy
66,711
+990
+2% +$74.7K 0.02% 245
2017
Q3
$5.06M Buy
65,721
+4,322
+7% +$326K 0.02% 238
2017
Q2
$4.59M Sell
61,399
-3,513
-5% -$249K 0.02% 234
2017
Q1
$4.32M Sell
64,912
-7,850
-11% -$523K 0.02% 234
2016
Q4
$4.75M Buy
72,762
+1,263
+2% +$81.9K 0.03% 213
2016
Q3
$5.06M Buy
71,499
+39,671
+125% +$2.89M 0.03% 196
2016
Q2
$2.35M Sell
31,828
-1,119
-3% -$77.3K 0.02% 303
2016
Q1
$2.14M Buy
32,947
+1,688
+5% +$115K 0.02% 303
2015
Q4
$2.41M Sell
31,259
-8,651
-22% -$687K 0.02% 272
2015
Q3
$3.29M Buy
39,910
+7,689
+24% +$684K 0.03% 209
2015
Q2
$2.84M Buy
32,221
+4,810
+18% +$441K 0.03% 227
2015
Q1
$2.42M Buy
27,411
+950
+4% +$84.3K 0.02% 244
2014
Q4
$2.2M Sell
26,461
-3,164
-11% -$262K 0.02% 254
2014
Q3
$2.5M Buy
29,625
+8,143
+38% +$659K 0.03% 207
2014
Q2
$1.74M Buy
21,482
+2,094
+11% +$165K 0.02% 255
2014
Q1
$1.48M Buy
19,388
+1,927
+11% +$140K 0.02% 263
2013
Q4
$1.26M Sell
17,461
-1,175
-6% -$81.7K 0.02% 258
2013
Q3
$1.28M Buy
18,636
+6,966
+60% +$461K 0.03% 221
2013
Q2
$739K Buy
+11,670
New +$759K 0.02% 300

Other funds holding NVS

Creative Planning's NVS Position: Q1 2026 in Review

Creative Planning increased its Novartis (NVS) stake by 20% in Q1 2026, buying an estimated $13.8M and bringing the position to 528,814 shares worth $80.8M. The position accounts for 0.05% of the portfolio, ranked #149.

Creative Planning first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Creative Planning held 528,814 shares of Novartis worth $80.8M as of Q1 2026.
  • Creative Planning bought 89,851 Novartis shares in Q1 2026, an estimated $13.8M.
  • Novartis made up 0.05% of Creative Planning's portfolio in Q1 2026, its #149 holding.
  • Creative Planning first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.